A randomized controlled trial of the Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C) to improve serious mental illness outcomes in a community setting.

Allison G Harvey,Lu Dong,Kerrie Hein,Stephanie H Yu,Armando J Martinez,Nicole B Gumport,Freddie L Smith,Aaron Chapman,Michael Lisman,Isaac A Mirzadegan,Alice C Mullin,Eve Fine,Emily A Dolsen,Caitlin E Gasperetti,Jorin Bukosky,Cynthia G Alvarado-Martinez,Amy M Kilbourne,Sophia Rabe-Hesketh,Daniel J Buysse,Allison G. Harvey,Stephanie H. Yu,Armando J. Martinez,Nicole B. Gumport,Freddie L. Smith,Isaac A. Mirzadegan,Alice C. Mullin,Michael R. Dolsen,Caitlin E. Gasperetti,Cynthia G. Alvarado-Martinez,Amy M. Kilbourne,Daniel J. Buysse
DOI: https://doi.org/10.1037/ccp0000650
2021-06-01
Journal of Consulting and Clinical Psychology
Abstract:Objective: To determine if the Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C) improves functional impairment, psychiatric symptoms, and sleep and circadian functioning. Method: Adults diagnosed with serious mental illness (SMI) and sleep and circadian dysfunction (N = 121) were randomly allocated to TranS-C plus usual care (TranS-C + UC; n = 61; 8 individual weekly sessions) or 6 months of Usual Care followed by Delayed Treatment with TranS-C (UC-DT; n = 60). Schizophrenia (45%) and anxiety disorders (47%) were common. Blind assessments were conducted pre-treatment, post-treatment, and 6 months later (6FU). The latter two were the post-randomization points of interest. The location was Alameda County Behavioral Health Care Services (ACBHCS), a Community Mental Health Center (CMHC) in California. Results: For the primary outcomes, relative to UC-DT, TranS-C + UC was associated with reduction in functional impairment (b = −3.18, p = 0.025, d = −0.58), general psychiatric symptoms (b = −5.88, p = 0.001, d = −0.64), sleep disturbance (b = −5.55, p < .0001, d = −0.96), and sleep-related impairment (b = −9.14, p < .0001, d = −0.81) from pre-treatment to post-treatment. These effects were maintained to 6-month follow-up (6FU; d = −0.42 to −0.82), except functional impairment (d = −0.37). For the secondary outcomes, relative to UC-DT, TranS-C + UC was associated with improvement in sleep efficiency and on the Sleep Health Composite score from pre-treatment to 6FU. TranS-C + UC was also associated with reduced total wake time and wake time variability from pre-treatment to post-treatment, as well as reduced hallucinations and delusions, bedtime variability, and actigraphy measured waking activity count variability from pre-treatment to 6FU. Conclusions: A novel transdiagnostic treatment, delivered within a CMHC setting, improves selected measures of functioning, symptoms of comorbid disorders, and sleep and circadian outcomes. (PsycInfo Database Record (c) 2021 APA, all rights reserved)
psychology, clinical
What problem does this paper attempt to address?